Condition (MeSH)
Empty Sella Syndrome
ClinicalTrials.gov lists 1 trial for Empty Sella Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
5 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Empty Sella Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Empty Sella Syndrome trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2019 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Empty Sella Syndrome trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Not applicable | 1 |
How many Empty Sella Syndrome trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Empty Sella Syndrome? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Visual disturbances associated with primary empty sella syndrome in patients with chronic renal failure. | Annals of ophthalmology | 1992 | Yes |
| Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. | Pituitary | 2008 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.